Last reviewed · How we verify
Comparator: Varivax
Varivax is a live attenuated varicella-zoster virus vaccine that stimulates immune response to prevent chickenpox infection.
Varivax is a live attenuated varicella-zoster virus vaccine that stimulates immune response to prevent chickenpox infection. Used for Prevention of varicella (chickenpox) in children and adults.
At a glance
| Generic name | Comparator: Varivax |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Live attenuated vaccine |
| Target | Varicella-zoster virus (VZV) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Varivax contains a weakened form of the varicella-zoster virus (VZV) that replicates in the body at low levels, triggering both cellular and humoral immune responses without causing disease. This vaccination induces protective antibodies and cell-mediated immunity against VZV, preventing or significantly reducing the severity of chickenpox infection upon natural exposure.
Approved indications
- Prevention of varicella (chickenpox) in children and adults
Common side effects
- Injection site reactions (erythema, swelling, pain)
- Fever
- Varicella-like rash (vaccine strain)
- Myalgia
Key clinical trials
- Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine (PHASE1, PHASE2)
- The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept (PHASE2)
- Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029) (PHASE3)
- Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026) (PHASE3)
- Safety and Immunogenicity of the rVSVΔG-ZEBOV-GP Ebola Virus Vaccine Candidate in Children Living in Lambaréné, Gabon (PHASE1, PHASE2)
- A Study of MG1111 in Healthy Children (PHASE2, PHASE3)
- Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007) (PHASE3)
- Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Comparator: Varivax CI brief — competitive landscape report
- Comparator: Varivax updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI